Convection-Enhanced Delivery for Neurodegeneration

📖 Wiki Page

therapeutic919 wordssynced 2026-04-02

Convection-Enhanced Delivery for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Convection-Enhanced Delivery for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Drug Delivery Technology</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Brain tumors, Parkinson's, Alzheimer's, ALS</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Bulk flow infusion under pressure for distributed drug delivery</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical Trials (Phase I/II)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Convection-Enhanced</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Pressure-driven bulk flow</td>
</tr>
<tr>
<td class="label">Volume</td>
<td>Predictable, scalable</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>All sizes</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Hours to days</td>
</tr>
<tr>
<td class="label">Coverage</td>
<td>1-10 cm³ per catheter</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>AAV-GDNF</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AADC</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Gill et al.</td>
<td>2003</t

...

Convection-Enhanced Delivery for Neurodegeneration

Overview

Introduction

Convection-Enhanced Delivery (CED) is an advanced technique for delivering therapeutic agents directly into brain tissue by applying hydrostatic pressure to create bulk flow. This method overcomes the limitations of diffusion-based delivery, enabling uniform distribution of large molecules, nanoparticles, and genes throughout targeted brain regions.

Technical Principles

Mechanism of Action

CED uses the following principle:

Infusion catheter placed in target brain region

Positive pressure applied via infusion pump (typically 0.5-10 μL/min)

Bulk flow creates interstitial distribution

Uniform coverage achieved beyond catheter tip

Comparison with Diffusion

Clinical Applications

Parkinson's Disease

Alzheimer's Disease

Anti-amyloid antibodies (e.g., aducanumab, lecanemab)
Anti-[tau](/proteins/tau) therapies
Neurotrophic factors (BDNF, NGF)
Gene therapy vectors

ALS

Antisense oligonucleotides
Neurotrophic factors
VEGF delivery
Stem cells

Brain Tumors

Chemotherapy agents (e.g., paclitaxel, topotecan)
Immunotoxins
Viral vectors

Equipment and Technique

Catheter Systems

Single-lumen catheters - Standard CED

Dual-lumen catheters - Reflux prevention

Multiple microcatheters - Extended coverage

Smart catheters - Real-time pressure monitoring

Infusion Parameters

Pressure: 5-100 mmHg
Rate: 0.5-10 μL/min (typically 1-5 μL/min)
Volume: 0.5-10 mL per infusion
Duration: 4-48 hours per treatment

Imaging Guidance

MRI - Real-time visualization with gadolinium
CT - Anatomical planning
PET - Target verification

Advantages

Bypasses [BBB](/entities/blood-brain-barrier) - Direct brain delivery

Predictable distribution - Pressure-controlled

Large molecule delivery - Proteins, antibodies, genes

Reduced systemic toxicity - Local delivery

Repeatable treatments - Implantable ports

Targeted delivery - Specific brain regions

Challenges and Limitations

Technical Challenges

Reflux - Backflow along catheter track

Infusion rate optimization - Balance of distribution vs. pressure

Catheter placement accuracy - Requires precise targeting

Distribution heterogeneity - Tissue variability

Safety Concerns

Increased intracranial pressure - Large volumes

Tissue damage - High pressure/flow rates

Infection risk - Indwelling catheters

Brain edema - Fluid extravasation

Clinical Evidence

Parkinson's Disease Trials

Current Trials

CED of AAV-GDNF for advanced PD
CED of AADC gene therapy for PD
CED of topotecan for gliomas

Future Directions

Emerging Applications

Gene therapy - AAV, lentiviral vectors

Combination therapy - Multiple agents

Stem cell delivery - Neural progenitors

RNAi/antisense - Gene silencing

CAR-T cells - Immunotherapy

Technology Improvements

Real-time MRI monitoring - Improved distribution

Smart catheters - Pressure/reflux control

Novel formulations - Enhanced convection

Automated systems - Precision infusion

Background

The study of Convection Enhanced Delivery For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[NIH - CED Research](https://www.nih.gov/)
[Parkinson's Foundation](https://www.parkinson.org/)
[American Brain Tumor Association](https://www.abta.org/)

References

[Bobo RH, et al, (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/8134401/)

[Morrison PF, et al, (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/8205544/)

[Gill SS, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12669033/)

[Lonser RR, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25479570/)

[Mehta AM, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28379661/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Convection-Enhanced Delivery for Neurodegeneration

Convection-Enhanced Delivery for Neurodegeneration

Overview

Convection-Enhanced Delivery for Neurodegeneration

Overview

Introduction

Technical Principles

Mechanism of Action

Comparison with Diffusion

Clinical Applications

Parkinson's Disease

Alzheimer's Disease

ALS

Brain Tumors

Equipment and Technique

Catheter Systems

Infusion Parameters

Imaging Guidance

Advantages

Challenges and Limitations

Technical Challenges

Safety Concerns

Clinical Evidence

Parkinson's Disease Trials

Current Trials

Future Directions

Emerging Applications

Technology Improvements

See Also

Background

Allen Brain Atlas Resources

External Links

References

Related Hypotheses